Takeaways Skyhawk’s global Phase 2/3 FALCON-HD program for SKY-0515 positions the company as a front-runner in disease‑modifying treatment for Huntington’s disease, and if successful, a once‑dai...
Takeaways Health Canada’s approval of Novartis’ Vanrafia (atrasentan) creates Canada’s first endothelin receptor antagonist–based therapy specifically for IgA nephropathy, giving clini...
Takeaways The Canadian NOC formally moves Scenesse from special‑access cases to on‑label, publicly or privately reimbursed treatment for erythropoietic protoporphyria, e...
Canada’s biotechnology industry is entering a defining era of scientific innovation, global investment, and clinical excellence. The Leading 10 Canadian Biotech Companies of 2026 report highligh...
Takeaways: The Canadian approval of Besremi gives PharmaEssentia a new, targeted therapy in the chronic myeloproliferative neoplasm space, expanding its hematology/oncology footprint beyond Taiw...
For most of modern medicine, the pharmaceutical industry has operated largely within a reactive healthcare model, developing therapies designed to treat diseases after they emerge. Today, however, adv...
Artificial intelligence is rapidly becoming embedded across the pharmaceutical value chain, from drug discovery and clinical trial optimization to manufacturing and commercialization. As the technolog...
Real world evidence (RWE) is rapidly reshaping how therapies are evaluated, approved, and commercialized within global healthcare systems, including Canadian Health. Derived from real world data such ...
The world’s population is aging at an unprecedented pace, creating one of the most significant long term shifts in global healthcare demand. By the coming decades, older adults will represent an incre...
Patient centricity has become one of the most widely used, and often overused, terms in the biopharma industry. In Canadian Health discussions, nearly every stakeholder references it in some form, emb...
